Pfizer reported Q3 earnings; discontinued the development of
Post# of 190
Posted On: 11/01/2016 10:33:06 AM
Pfizer reported Q3 earnings; discontinued the development of bococizumab.
Pfizer Earnings Snapshot Pfizer net income was down 38% and total revenues increased 8%. With regards to its segment, Innovative Health business revenue up 9%; Essential Health business grew 7% during the quarter. Also Pfizer announced the decision to discontinue the development of bococizumab, this will negatively impact the adjusted R&D expense by $0.3 billion.
Pfizer Earnings Snapshot Pfizer net income was down 38% and total revenues increased 8%. With regards to its segment, Innovative Health business revenue up 9%; Essential Health business grew 7% during the quarter. Also Pfizer announced the decision to discontinue the development of bococizumab, this will negatively impact the adjusted R&D expense by $0.3 billion.
(0)
(0)Pfizer Inc. (PFE) Stock Research Links
Scroll down for more posts ▼